Accelr8 Extends Evaluation Period with Novartis

Accelr8 said that it has received an aggregate amount of roughly $640,000 from Novartis so far under the technology evaluation agreement.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.